| SC 13G/A | 2024-02-23 | PERCEPTIVE ADVISORS LLC | enVVeno Medical Corp | 1,394,716 | 9.9% | EDGAR |
| SC 13G/A | 2024-02-14 | PERCEPTIVE ADVISORS LLC | enVVeno Medical Corp | 1,394,716 | 9.9% | EDGAR |
| SC 13G | 2024-02-14 | Nantahala Capital Management, LLC | enVVeno Medical Corp | 1,399,588 | 9.9% | EDGAR |
| SC 13G/A | 2023-02-14 | PERCEPTIVE ADVISORS LLC | enVVeno Medical Corp | 937,515 | 9.9% | EDGAR |
| SC 13G/A | 2022-02-14 | CVI Investments, Inc. | enVVeno Medical Corp | 280,357 | 2.9% | EDGAR |
| SC 13G/A | 2022-02-14 | PERCEPTIVE ADVISORS LLC | enVVeno Medical Corp | 954,248 | 9.9% | EDGAR |
| SC 13G/A | 2022-02-11 | INTRACOASTAL CAPITAL, LLC | enVVeno Medical Corp | 431,213 | 4.4% | EDGAR |
| SC 13G/A | 2022-01-19 | Empery Asset Management, LP | enVVeno Medical Corp | 471,579 | 4.7% | EDGAR |
| SC 13G | 2021-09-17 | PERCEPTIVE ADVISORS LLC | Hancock Jaffe Laboratories, Inc. | 954,248 | 9.9% | EDGAR |
| SC 13G | 2021-02-19 | CVI Investments, Inc. | Hancock Jaffe Laboratories, Inc. | 435,714 | 5.6% | EDGAR |
| SC 13G | 2021-02-17 | Empery Asset Management, LP | Hancock Jaffe Laboratories, Inc. | 571,428 | 7.4% | EDGAR |
| SC 13G/A | 2021-01-29 | INTRACOASTAL CAPITAL, LLC | Hancock Jaffe Laboratories, Inc. | 191,431 | 7.0% | EDGAR |
| SC 13G/A | 2021-01-20 | Empery Asset Management, LP | Hancock Jaffe Laboratories, Inc. | 185,868 | 5.0% | EDGAR |
| SC 13D/A | 2020-12-18 | FatBoy Capital, L.P. | Hancock Jaffe Laboratories, Inc. | 26,250 | 1.2% | EDGAR |
| SC 13D | 2020-12-16 | FatBoy Capital, L.P. | Hancock Jaffe Laboratories, Inc. | 156,250 | 6.9% | EDGAR |
| SC 13G | 2020-10-15 | Empery Asset Management, LP | Hancock Jaffe Laboratories, Inc. | 3,084,112 | 6.2% | EDGAR |
| SC 13G | 2020-07-30 | INTRACOASTAL CAPITAL, LLC | Hancock Jaffe Laboratories, Inc. | 4,045,426 | 10.0% | EDGAR |
| SC 13G | 2020-06-11 | INTRACOASTAL CAPITAL, LLC | Hancock Jaffe Laboratories, Inc. | 1,257,837 | 5.0% | EDGAR |
| SC 13G | 2019-02-14 | Zhivilo Yury | Hancock Jaffe Laboratories, Inc. | 4,478,581 | 38.2% | EDGAR |
| SC 13G/A | 2018-12-26 | ACT Capital Management, LLLP | Hancock Jaffe Laboratories, Inc. | 503,500 | 4.3% | EDGAR |